([(3,5-dimethylisoxazol-4-yl)methyl]thio)acetic acid | 446830-00-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: ([(3,5-dimethylisoxazol-4-yl)methyl]thio)acetic acid
• 英文别名: 2-(((3,5-dimethylisoxazol-4-yl)methyl)thio)acetic acid；2-[(3,5-dimethyl-1,2-oxazol-4-yl)methylsulfanyl]acetic acid
• CAS: 446830-00-8
• 化学式: C₈H₁₁NO₃S
• mdl: MFCD03011609
• 分子量: 201.246
• InChiKey: UFJHCGXCDQLCMZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  88.6
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• 海关编码：
  2934999090

反应信息

• 作为反应物：
  描述：

  ([(3,5-dimethylisoxazol-4-yl)methyl]thio)acetic acid 在 叠氮磷酸二苯酯 、 三乙胺 作用下， 以 甲苯 为溶剂， 反应 1.0h， 生成 4-(Isocyanatomethylsulfanylmethyl)-3,5-dimethyl-1,2-oxazole
  参考文献：
  名称：

  核雄激素受体的小分子拮抗剂治疗去势抵抗性前列腺癌

  摘要：

  在高通量筛选活动确定了硫醚1是核雄激素受体的拮抗剂后，开发了一种用于结构-活性关系（SAR）目的的区域模型，并合成了类似物并在基于细胞的萤光素酶测定法中进行了评估。一种新型的硫醚等排物，环丙烷（1 S，2 R）-27，显示出所需的增强的效能和结构特性（立体比SAR响应，不存在容易氧化的硫原子，低分子量，柔性键数量减少和极性表面积） ，以及药物相似性得分）在C4-2-PSA-rl细胞中的前列腺特异性抗原荧光素酶测定中，有资格作为前列腺癌药物开发的新先导结构。

  DOI：

  10.1021/acsmedchemlett.6b00186

文献信息

• SMALL MOLECULE INHIBITORS OF THE NUCLEAR TRANSLOCATION OF ANDROGEN RECEPTOR FOR THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER
  申请人：University of Pittsburgh - Of the Commonwealth System of Higher Education

  公开号：US20160257657A1

  公开（公告）日：2016-09-08

  A compound, or a pharmaceutically acceptable salt or ester thereof, according to formula I: R 20 —(Z) b —(Y) c —(R 21 ) a —(X) d —R 22 —R 23 wherein R 20 is aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, substituted heterocycloalkyl, alkoxy, aryloxy, a thio-containing group, or a seleno-containing group; Z is alkanediyl, substituted alkanediyl, cycloalkanediyl, or substituted cycloalkanediyl; Y is S, O, S(═O), —S(═O)(═O)—, or NR 10 , wherein R 10 is H or alkyl; R 21 is alkanediyl, substituted alkanediyl, cycloalkanediyl, substituted cycloalkanediyl alkadienyl, substituted alkadienyl, alkatrienyl, substituted alkatrienyl; X is —C(═O)—, —S(═O)(═O)—, or —N(H)C(═O)—; R 22 includes at least one divalent amino radical; R 23 is aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, substituted heterocycloalkyl, alkoxy, aryloxy, a thio-containing group, or a seleno-containing group; a, b, c, and d independently are 0 or 1.

  根据公式I，化合物或其药学上可接受的盐或酯，其中R20为芳基，取代芳基，杂环芳基，取代杂环芳基，杂环烷基，取代杂环烷基，烷氧基，芳基氧基，含硫基或含硒基；Z为烷二基，取代烷二基，环烷二基或取代环烷二基；Y为S，O，S(═O)，—S(═O)(═O)—或NR10，其中R10为H或烷基；R21为烷二基，取代烷二基，环烷二基，取代环烷二基，烯丙基，取代烯丙基，烯三基或取代烯三基；X为—C(═O)—，—S(═O)(═O)—或—N(H)C(═O)—；R22至少包括一个二价氨基基团；R23为芳基，取代芳基，杂环芳基，取代杂环芳基，杂环烷基，取代杂环烷基，烷氧基，芳基氧基，含硫基或含硒基；a、b、c和d独立地为0或1。
• COMPOUNDS FOR TREATING PROSTATE CANCER
  申请人：UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION

  公开号：US20160264540A1

  公开（公告）日：2016-09-15

  A compound, or a pharmaceutically acceptable salt or ester thereof, having a formula I of: R 20 —(Z) b —(Y) c —(R 21 ) a —X—R 22 -R 23 wherein R20 is an aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, substituted heterocycloalkyl, alkoxy, aryloxy, a silyl-containing group, a boryl-containing group, a phosphine-containing group, amino, a thio-containing group, a seleno-containing group, halide, or a nitro-containing group; Z is alkanediyl, substituted alkanediyl, cycloalkanediyl, or substituted cycloalkanediyl; Y is S, O, or NR 10 , wherein R 10 is H or alkyl; R 21 is alkanediyl, substituted alkanediyl, cycloalkanediyl, substituted cycloalkanediyl, alkadienyl, substituted alkadienyl, alkatrienyl, substituted alkatrienyl; X is —C(=0)- or —S(=0)(=0)-; R 22 is a moiety that includes at least one divalent amino radical; R 23 is an aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, substituted heterocycloalkyl, alkoxy, aryloxy, a silyl-containing group, a boryl-containing group, a phosphine-containing group, amino, a thio-containing group, a seleno-containing group, halide, or a nitro-containing group; a is 0 or 1; b is 0 or 1; and c is 0 or 1; provided that if X is —C(=0)- then Y is not S.

  化合物，或其药学上可接受的盐或酯，其具有公式I：R20—(Z)b—(Y)c—(R21)a—X—R22-R23，其中R20是芳基，取代芳基，杂环芳基，取代杂环芳基，杂环烷基，取代杂环烷基，烷氧基，芳氧基，含硅基团，含硼基团，含膦基团，氨基，含硫基团，含硒基团，卤素或含硝基团；Z是烷二基，取代烷二基，环烷二基或取代环烷二基；Y是S，O或NR10，其中R10是H或烷基；R21是烷二基，取代烷二基，环烷二基，取代环烷二基，烯二基，取代烯二基，烯三基，取代烯三基；X是—C（=0）-或—S（=0）（=0）-；R22是至少包含一个双价氨基基团的基团；R23是芳基，取代芳基，杂环芳基，取代杂环芳基，杂环烷基，取代杂环烷基，烷氧基，芳氧基，含硅基团，含硼基团，含膦基团，氨基，含硫基团，含硒基团，卤素或含硝基团；a为0或1；b为0或1；c为0或1；但如果X是—C（=0）-，则Y不是S。
• Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer
  申请人：University of Pittsburgh-Of the Commonwealth System of Higher Education

  公开号：US10544110B2

  公开（公告）日：2020-01-28

  A compound, or a pharmaceutically acceptable salt or ester thereof, according to formula I: R20—(Z)b—(Y)c—(R21)a—(X)d—R22—R23 wherein R20 is aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, substituted heterocycloalkyl, alkoxy, aryloxy, a thio-containing group, or a seleno-containing group; Z is alkanediyl, substituted alkanediyl, cycloalkanediyl, or substituted cycloalkanediyl; Y is S, O, S(═O), —S(═O)(═O)—, or NR10, wherein R10 is H or alkyl; R21 is alkanediyl, substituted alkanediyl, cycloalkanediyl, substituted cycloalkanediyl alkadienyl, substituted alkadienyl, alkatrienyl, substituted alkatrienyl; X is —C(═O)—, —S(═O)(═O)—, or —N(H)C(═O)—; R22 includes at least one divalent amino radical; R23 is aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, substituted heterocycloalkyl, alkoxy, aryloxy, a thio-containing group, or a seleno-containing group; a, b, c, and d independently are 0 or 1.

  一种符合式 I 的化合物或其药学上可接受的盐或酯： R20-(Z)b-(Y)c-(R21)a-(X)d-R22-R23 其中 R20 是芳基、取代的芳基、杂芳基、取代的杂芳基、杂环烷基、取代的杂环烷基、烷氧基、芳氧基、含硫醚基团或含硒基团；Z 是烷二基、取代的烷二基、环烷二基或取代的环烷二基； Y 是 S、O、S(═O)、-S(═O)(═O)- 或 NR10，其中 R10 是 H 或烷基；R21 是烷二基、取代的烷二基、环烷二基、取代的环烷二基 烷二烯基、取代的烷二烯基、烷三烯基、取代的烷三烯基；X 是 -C(═O)-、-S(═O)(═O)- 或 -N(H)C(═O)-；R22 包括至少一个二价氨基；R23 是芳基、取代的芳基、杂芳基、取代的杂芳基、杂环烷基、取代的杂环烷基、烷氧基、芳氧基、含硫醚基团或含硒基团；a、b、c 和 d 独立地为 0 或 1。
• Compounds for treating prostate cancer
  申请人：University of Pittsburgh—of the Commonwealth System of Higher Education

  公开号：US10882834B2

  公开（公告）日：2021-01-05

  A compound, or a pharmaceutically acceptable salt or ester thereof, having a formula I of: R20—(Z)b—(Y)c—(R21)a—X—R22—R23 wherein R20 is an aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, substituted heterocycloalkyl, alkoxy, aryloxy, a silyl-containing group, a boryl-containing group, a phosphine-containing group, amino, a thio-containing group, a seleno-containing group, halide, or a nitro-containing group; Z is alkanediyl, substituted alkanediyl, cycloalkanediyl, or substituted cycloalkanediyl; Y is S, O, or NR10, wherein R10 is H or alkyl; R21 is alkanediyl, substituted alkanediyl, cycloalkanediyl, substituted cycloalkanediyl, alkadienyl, substituted alkadienyl, alkatrienyl, substituted alkatrienyl; X is —C(=0)- or —S(=0)(=0)-; R22 is a moiety that includes at least one divalent amino radical; R23 is an aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, substituted heterocycloalkyl, alkoxy, aryloxy, a silyl-containing group, a boryl-containing group, a phosphine-containing group, amino, a thio-containing group, a seleno-containing group, halide, or a nitro-containing group; a is 0 or 1; b is 0 or 1; and c is 0 or 1; provided that if X is —C(=0)- then Y is not S.

  一种化合物或其药学上可接受的盐或酯，其式 I 为R20-(Z)b-(Y)c-(R21)a-X-R22-R23 其中 R20 是芳基、取代的芳基、杂芳基、取代的杂芳基、杂环烷基、取代的杂环烷基、烷氧基、芳氧基、含硅基的基团、含硼酸基的基团、含膦基的基团、氨基、含硫基的基团、含硒基的基团、卤化物或含硝基的基团；Z是烷二基、取代的烷二基、环烷二基或取代的环烷二基；Y是S、O或NR10，其中R10是H或烷基；R21是烷二基、取代的烷二基、环烷二基、取代的环烷二基、烷二烯基、取代的烷二烯基、烷三烯基、取代的烷三烯基；X 是-C(=0)-或-S(=0)(=0)-； R22 是包括至少一个二价氨基的分子；R23 是芳基、取代的芳基、杂芳基、取代的杂芳基、杂环烷基、取代的杂环烷基、烷氧基、芳氧基、含硅烷基的基团、含硼酸基的基团、含膦基的基团、氨基、含硫基的基团、含硒基的基团、卤化物或含硝基的基团；a 是 0 或 1；b 是 0 或 1；c 是 0 或 1；条件是如果 X 是 -C(＝0)-，则 Y 不是 S。
• [EN] COMPOUNDS FOR TREATING PROSTATE CANCER<br/>[FR] COMPOSÉS DESTINÉS AU TRAITEMENT DU CANCER DE LA PROSTATE
  申请人：UNIV PITTSBURGH

  公开号：WO2015042297A8

  公开（公告）日：2016-02-25